Landmark trials such as EMPA‐REG OUTCOME (2015) and DAPA‐HF (2019) demonstrated reductions in heart failure hospitalizations [19,20], and the LEADER trial (2016) showed decreased cardiovascular mortality with glucagon-like peptide-1 receptor agonists (GLP‐1 RAs) [21]. This evidence concerns the gene GLP1R and heart failure.